Equity Profile

NUVL

Nuvalent, Inc.

Health CareBiotechnology$9.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Although revenue estimates are not available, any growth in revenue would signal positive demand for Nuvalent's therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

NUVL Q2-2026 Earnings Preview

Context

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer. With a market cap of $10 billion, it operates in the health care sector, which is increasingly important as advancements in personalized medicine continue to shape treatment options for patients.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-1.06%

Last Quarter Recap

In Q1-2026, Nuvalent reported an EPS of -$1.39, slightly missing expectations. The stock reacted negatively, dropping 1.78% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's history of missing EPS estimates. The lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Nuvalent can demonstrate improved operational efficiency and better-than-expected EPS, it could regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to provide guidance, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's recent history of missing EPS estimates, this number will be crucial in determining market sentiment.

Will there be any guidance on revenue growth?

Investors will be looking for indications of future performance, especially in the context of product demand and market conditions.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Nuvalent's potential for a turnaround, as recent product developments could indicate stronger demand than anticipated.

Supporting Evidence

The options market is pricing a 3.9% move, suggesting investors are bracing for volatility, which could indicate hidden optimism.

Despite recent misses, the stock has shown resilience in previous quarters, bouncing back after negative earnings.

Key Risk

If the EPS comes in better than expected, it could shift the narrative and lead to a significant upward adjustment in stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether Nuvalent can turn around its recent performance and provide a clearer path to profitability.

Bull Confirmed If

A reported EPS of -$1.20 or better would suggest improved financial health and could boost investor confidence.

Bear Confirmed If

An EPS worse than -$1.50 would reinforce concerns about the company's financial trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±3.9%

Historical Avg

±3.9%

In line with history

The options market is pricing in a move of about 3.9% in either direction, indicating uncertainty around the earnings report.

Options are pricing ±3.9% while NUVL has averaged ±3.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

31.9%

Calls (3K)P/C Ratio: 0.36Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing in-line setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.8%, with a raw directional average of -1.5% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nuvalent beats expectations, history suggests the stock could rise by an average of 3.9%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors digest management's commentary.

Miss

A miss could lead to a decline of around 1.06% on average, reinforcing negative sentiment around the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected timelines.
2Management's commentary on operational efficiencies and cost management strategies.
3Insights into market demand for Nuvalent's therapies and competitive positioning.
4Any guidance on future revenue expectations or market conditions.
5Discussion of partnerships or collaborations that could enhance growth prospects.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Nuvalent, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Although revenue estimates are not available, any growth in revenue would signal positive demand for Nuvalent's therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

NUVL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-1.06%

Last Quarter Recap

In Q1-2026, Nuvalent reported an EPS of -$1.39, slightly missing expectations. The stock reacted negatively, dropping 1.78% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's history of missing EPS estimates. The lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Nuvalent can demonstrate improved operational efficiency and better-than-expected EPS, it could regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to provide guidance, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's recent history of missing EPS estimates, this number will be crucial in determining market sentiment.

Will there be any guidance on revenue growth?

Investors will be looking for indications of future performance, especially in the context of product demand and market conditions.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Nuvalent's potential for a turnaround, as recent product developments could indicate stronger demand than anticipated.

Supporting Evidence

The options market is pricing a 3.9% move, suggesting investors are bracing for volatility, which could indicate hidden optimism.

Despite recent misses, the stock has shown resilience in previous quarters, bouncing back after negative earnings.

Key Risk

If the EPS comes in better than expected, it could shift the narrative and lead to a significant upward adjustment in stock price.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether Nuvalent can turn around its recent performance and provide a clearer path to profitability.

Bull Confirmed If

A reported EPS of -$1.20 or better would suggest improved financial health and could boost investor confidence.

Bear Confirmed If

An EPS worse than -$1.50 would reinforce concerns about the company's financial trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±3.9%

Historical Avg

±3.9%

In line with history

The options market is pricing in a move of about 3.9% in either direction, indicating uncertainty around the earnings report.

Options are pricing ±3.9% while NUVL has averaged ±3.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

31.9%

Calls (3K)P/C Ratio: 0.36Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing in-line setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nuvalent beats expectations, history suggests the stock could rise by an average of 3.9%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors digest management's commentary.

Miss

A miss could lead to a decline of around 1.06% on average, reinforcing negative sentiment around the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected timelines.
2Management's commentary on operational efficiencies and cost management strategies.
3Insights into market demand for Nuvalent's therapies and competitive positioning.
4Any guidance on future revenue expectations or market conditions.
5Discussion of partnerships or collaborations that could enhance growth prospects.